Efficacy and safety of alosetron in women with irritable bowel syndrome: A randomised, placebo-controlled trial

Michael Camilleri, Allison R. Northcutt, Steven Kong, George E. Dukes, David McSorley, Allen W. Mangel

Research output: Contribution to journalArticle

505 Scopus citations

Abstract

Background. Irritable bowel syndrome (IBS) is a common gastrointestinal disorder with symptoms of abdominal pain, discomfort, and altered bowel function. Antagonists of the type 3 serotonin receptor (5-HT3) have shown promising results in the relief of IBS-associated symptoms. We aimed to confirm these findings by doing a randomised, placebo-controlled trial. Methods. We studied 647 female IBS patients with diarrhoea-predominant or alternating bowel patterns (diarrhoea and constipation). 324 patients were assigned 1 mg alosetron and 323 placebo orally twice daily for 12 weeks, followed by a 4-week post-treatment period. Adequate relief of abdominal pain and discomfort was the primary endpoint; secondary endpoints included improvements in urgency, stool frequency, and stool consistency. Analysis was by intention to treat. Findings. 79 (24%) of patients in the alosetron group and 53 (16%) in the placebo group dropped out. The difference in the drop-out rate between groups was mainly due to a greater occurrence of constipation in the alosetron group. A greater proportion of alosetron-treated patients than placebo-treated patients (133 [41%] vs 94 [29%], respectively) reported adequate relief for all 3 months of treatment (difference 12% [4.7-19.2]). Alosetron also significantly decreased urgency and stool frequency, and increased stool firmness. Constipation occurred in 30% and 3% of patients in the alosetron and placebo groups, respectively. Interpretation. Alosetron was well tolerated and clinically effective in alleviating pain and bowel-related symptoms in this population of women with IBS.

Original languageEnglish (US)
Pages (from-to)1035-1040
Number of pages6
JournalLancet
Volume355
Issue number9209
DOIs
StatePublished - Mar 25 2000

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Efficacy and safety of alosetron in women with irritable bowel syndrome: A randomised, placebo-controlled trial'. Together they form a unique fingerprint.

  • Cite this